In early March of 2018, at age 58, Roger Miller went to a local doctor’s office in Maine for outpatient surgery. He’d been putting off getting what he’d thought was a cyst removed from the back of his head. During the procedure, he overheard the surgeon say, “Oh, this doesn’t look good.” Miller, who at … Read more
Animals — from oysters and corals to flies and mammals — encode proteins to sense their environment and share a common strategy to rally a defense. Scientists have identified a new family of immune proteins conserved across animal evolution with common features. Recent research from Dana-Farber Cancer Institute has added a new family to the … Read more
Like a mill crumbling into a river, solid tumors constantly shed bits of themselves — including their DNA — into the bloodstream. This free-floating genetic material, known as circulating tumor DNA, or ctDNA, contains a trove of information about the tumor. Advances in technology have made it possible to extract ctDNA from a blood sample, … Read more
For years, patients with advanced forms of gastric and esophageal cancer have had relatively few treatment options. Most patients with inoperable tumors would receive chemotherapy, usually a combination of fluorouracil, oxaliplatin and leucovorin (known as FOLFOX). While this regimen is often effective, patients eventually develop resistance to the treatment and their tumors progress. Now, the … Read more
In a branch of the PI3K protein family — with members named PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ — PI3Kβ was long treated as the proverbial middle child: neglected by cancer scientists in favor of its more prominent siblings. In a new study, Dana-Farber researchers demonstrate that it doesn’t deserve its obscurity — that in fact … Read more
When the time came for Jeffrey Ferreira to undergo a stem cell transplant for acute myeloid leukemia (AML), his Dana-Farber hematologist, Corey Cutler, MD, MPH, had some intriguing news: he was eligible for a clinical trial of a new approach to lowering the risk of chronic graft-versus-host disease (GVHD), a common and sometimes severe aftereffect … Read more
When scientists named microglial cells after the Greek word for “glue,” they thought it conveyed all one needed to know about the cells. The cells’ role, it was believed, began and ended with providing connective tissue for neurons, the information carriers of the nervous system. Research over many years has shown that moniker to … Read more
On a wave of promising research and positive media stories, psychedelic drugs are edging closer to mainstream use for treating a variety of mental disorders. A clinical trial recently launched by Dana-Farber investigators is the first to evaluate such an agent in patients receiving hospice care. The trial, which plans to enroll 15 patients served … Read more
When researchers report the survival effect of a cancer drug in a clinical trial, they almost always use a measure called hazard ratio. For all its ubiquity, however, hazard ratio has a hazard of its own: it’s a bit tricky to understand. A 2019 study found that 47% of researchers misinterpreted hazard ratio (HR) when … Read more
For nearly a century, scientists have appreciated that cancer cells rely on a process called glycolysis to grow and divide at very high rates. In the process, the cells avidly break down glucose to produce lactate, which has been considered a passive by-product — a mechanism known as the Warburg Effect, named after the German … Read more
A novel hematopoietic stem cell transplantation (HSCT) method utilizing ‘graft sculpting’ is being tested in a phase 1 clinical trial in patients with refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are at the highest risk of relapse after ‘standard’ transplants. In fact, the patients in the trial don’t qualify for a standard … Read more
Waldenström’s macroglobulinemia (WM) is a blood cancer that is extremely rare, affecting around 1500 people in the US each year. About 20 percent of those cases are considered familial, meaning that many members of the same family also have some form of blood cancer, such as myeloma or lymphoma. An even smaller group — five … Read more
Even as an infant is learning to distinguish herself from the rest of the world, a key part of her immune system is working toward the same goal, albeit in a very different manner. From before birth through the early years of life, young immune system cells in the thymus gland are receiving an education … Read more
A study led by Dana-Farber researchers has revealed that inherited variations in certain DNA damage repair genes may increase an individual’s susceptibility to Ewing sarcoma, an aggressive cancer that tends to strike teenagers and young adults. Ewing sarcoma is rare, with only about one in a million cases diagnosed annually in the United States, and … Read more
Pancreatic cancer cells operate a recycling program that would be the envy of any municipality — but the only beneficiaries are the cells themselves. All cells in the body recycle minerals and nutrients, removing them from storage and breaking them down them for re-use. But in cancer cells, this process, known as autophagy — literally, … Read more
To understand the genesis of the bone marrow transplant field, go back to the detonation, in 1945, of the first nuclear weapons and the shadow of the Atomic Age. The search for ways to rescue the blood-forming and immune systems of individuals exposed to high doses of radiation provided the impetus for donor bone marrow … Read more
Logic said that drugs known as PARP inhibitors would work as well — and perhaps even better — in breast cancer marked by BRCA gene mutations than in ovarian cancer carrying the same abnormalities. Clinical results said otherwise. Patients with relapsed, BRCA-mutated ovarian cancer survive longer, overall, with PARP inhibitor treatment than any other therapy. … Read more
An exercise-related hormone, irisin, administered to animals with a model of Parkinson’s disease reduced nerve degeneration and symptoms associated with the progressive movement disorder, say scientists from Dana-Farber and Johns Hopkins Medicine. About one million people in the United States, and 10 million people worldwide are living with Parkinson’s, which is characterized by tremors, slowed … Read more
Of all the mutated, blundering, havoc-wreaking genes in cancer cells, few are more ubiquitous than TP53. The gene, which in its normal, capable form is nicknamed the “guardian of the genome,” is found in a flawed form in almost every type of cancer, including up to half of all lung, ovarian, and colorectal cancers and … Read more
Discovered only about a decade ago, a key actor in the immune system called STING has become a hot target of research aimed at improving cancer immunotherapy. STING (stimulator of interferon genes) has been called a “master regulator” of the innate immune response against cancer. When activated by substances called agonists, STING turns on genes … Read more